AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02194413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02194413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02194413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02194413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00544206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard enteral feeding product
Description: 16 hrs daily x 5 days
Study NCT00544206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specific feeding product
Description: 16 hrs daily for 5 days
Study NCT01777867 — intervention group
Intervention type: PROCEDURE
Intervention: Cough Reflex Sensitivity
Description: Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
Study NCT01777867 — intervention group
Intervention type: PROCEDURE
Intervention: Methacholine Challenge
Description: A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
Study NCT04493073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ologen Collagen Implant
Description: Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
Study NCT04493073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C Kyowa®
Description: Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
Study NCT02015754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEBIRI
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
Study NCT02015754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead M1
Description: The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
Study NCT02015754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
Study NCT02294955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterablation
Description: Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
Study NCT02294955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
Study NCT02294955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: Dosage orally 80-160 mg twice daily
Study NCT02294955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
Study NCT02294955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: Dosage orally 300 mg twice daily
Study NCT02747602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (standard breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
Study NCT02747602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride oil (high fat breakfast)
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Study NCT01787760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Soft Contact Lens B
Description: Test lenses to be worn in daily wear modality
Study NCT01787760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Soft Contact Lens C
Description: Test lenses to be worn in a daily wear modality
Study NCT01787760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Control spectacle lenses to be worn in a daily wear modality
Study NCT01348880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT, (Staxyn, BAY38-9456)
Description: Single dose of 10 mg of vardenafil ODT, taken without water
Study NCT01348880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo to match 10 mg vardenafil ODT. taken without water
Study NCT01029717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard polyurethane Central Venous Catheter
Description: Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
Study NCT01029717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)
Description: Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
Study NCT01029717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin bonded polyurethane CVC
Description: Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
Study NCT03413748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective Cesarean Section
Description: lower segment cesarean section
Study NCT03413748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peritoneal irrigation
Description: Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
Study NCT03477149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easyx
Description: Embolization will be done with Easyx liquid agent.
Study NCT01656096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
Study NCT01656096 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Study NCT04114968 — intervention group
Intervention type: OTHER
Intervention: GP-based screening or HPV self-sampling
Description: Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
Study NCT00319228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-derived AT-III concentrate
Description: Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
Study NCT01469494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP flap breast reconstruction
Description: DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
Study NCT01469494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIEA flap breast reconstruction
Description: The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast.
Study NCT01628250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic complete mesocolic excision
Description: laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
Study NCT01628250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D3-laparoscopic colectomy
Description: D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
Study NCT02214316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Study NCT02833116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Study NCT02833116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT03251287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrate
Description: Single dose of 14mmol oral inorganic sodium nitrate
Study NCT03251287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of oral matching placebo
Study NCT03251287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Phosphorous Magnetic Resonance Spectroscopy
Description: On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
Study NCT03801499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT04408937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triopifexor
Description: Tropifexor as a dry blend in hard gelatin capsules for oral administration
Study NCT04408937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules for oral administration
Study NCT02021799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa and Lactobacillus rhamnosus GR-1
Study NCT01039142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
Study NCT01535144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fracture compressing screw ZfW 102 Königsee Implantate GmbH
Description: Comparison of two metallic implantable fracture compressing screws
Study NCT01535144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture compressing screw titanium Königsee Implantate GmbH
Description: Comparison of two metallic implantable fracture compressing screws
Study NCT02205307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT
Study NCT02205307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY Elite
Study NCT01353963 — intervention group
Intervention type: DRUG
Intervention: desvenlafaxine succinate
Description: 50 mg tablet once daily
Study NCT00993369 — intervention group
Intervention type: OTHER
Intervention: Holter monitor
Description: Record heart rate for 2 to 6 hours on day of life 1 or 2.
Study NCT00764231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
Study NCT00764231 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list
Description: Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
Study NCT03799536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotalol
Description: Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
Study NCT02445209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EOX
Description: combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
Study NCT03799536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalex
Description: Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
Study NCT00617201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Once daily oral dosing
Study NCT00617201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily oral dosing - matched placebo
Study NCT00856505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and mycophenolate sodium
Description: Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
Study NCT03251287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phosphorous Magnetic Resonance Spectroscopy
Description: On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
Study NCT03251287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Stress Transthoracic Echocardiogram
Description: On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
Study NCT04377048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: as described in NGS Arm
Study NCT04377048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: as described in NGS Arm
Study NCT04377048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-Gimeracil-Oteracil
Description: as described in NGS Arm
Study NCT02855619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Martin
Description: The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150).
Study NCT02855619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cader
Description: The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150).
Study NCT02855619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EDRIC
Description: The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150).
Study NCT00478452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-Ova
Study NCT00478452 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Ova with Cyclophosphamide
Study NCT01005329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01005329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01005329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01005329 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01005329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03944681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Droperidol Injectable Solution
Description: An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
Study NCT03251287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Stress Transthoracic Echocardiogram
Description: On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
Study NCT04855448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Hand S robot and da Vinci robot
Description: The surgeries are performed with the Micro Hand S robot and da Vinci robot
Study NCT04855448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: da Vinci robot
Description: The surgeries are performed with the da Vinci robot
Study NCT03121014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
Study NCT03121014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: targeting a 4800μM/min/ day from day -5 through day -2
Study NCT03121014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
Study NCT03121014 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: dose of 3Gy on days -3, -2 and -1
Study NCT03121014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Product Infusion
Description: Day 0 according to BMT unit policy
Study NCT03121014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
Study NCT03121014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
Study NCT03331614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flowaid FA-100 SCCD
Description: The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
Study NCT02282202 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oscillating Positive Expiratory Pressure (Aerobika ®)
Description: The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks.
Study NCT01876849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10 mcg, twice daily